GE Healthcare is collaborating in two clinical trials with the Tel Aviv Sourasky Medical Center in Tel Aviv, Israel, and the Hamilton Health Sciences Hospital in Hamilton, Ontario, on the use of a new technology that may assist in assessment and early detection of breast cancer in women who are at high risk for the disease.
The company said its investigational Molecular Breast Imaging (MBI) system is a gamma camera dedicated for breast imaging based on accumulation of a radioactive tracer in hypermetabolic cancer cells. It uses cadmium zinc telluride imaging detectors to replace the standard NaI detectors routinely used for gamma cameras. Early clinical work done in the Mayo Clinic in the U.S. shows encouraging results, GE said.
The team in Hamilton is running a prospective pilot study to explore the ability of GE's MBI system to detect breast cancer and to evaluate the feasibility, acceptability and safety of using a MBI gamma camera in women at high risk of developing breast cancer.
The Institute of Nuclear Medicine in the Tel Aviv Souraskiy Medical Center is running a clinical trial for early detection of breast cancer in women where current imaging techniques, mainly mammography, are less effective. The purpose of the study is to assess the clinical performance of the new technology specifically in areas where current clinical techniques are not optimal: women with dense breast tissue, after previous surgery and women with locally advanced breast cancer before and after neo-adjuvant chemotherapy.